

# Understanding **polycystic ovary syndrome**

**Key advisors:** Professor Cindy Farquhar and Associate Professor Neil Johnson, Department of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Auckland

## **Key messages:**

- Polycystic ovary syndrome (PCOS) is associated with a range of metabolic abnormalities which can lead to long term health problems
- PCOS is the most common endocrine disorder among young women
- PCOS is a syndrome so there is not a single diagnostic test
- Lifestyle changes play an important role in management of the syndrome
- Management should be individually tailored for each patient depending on the type of symptoms and clinical features found

## **Background**


PCOS is characterised by a varied and often complex array of metabolic and endocrine abnormalities. The syndrome was originally described by Stein and Leventhal in 1935, as a triad consisting of amenorrhoea, hirsutism and obesity, in women who had multiple cysts on their ovaries.<sup>1</sup> Over the last decade or so, the understanding of this syndrome has changed and the emphasis is often on the long-term consequences that may occur.

## **Prevalence of PCOS**

PCOS is the most common endocrine disorder among young women. Accurate prevalence figures are hard to find because of the lack of consensus that has existed regarding diagnosis,<sup>2</sup> however it is reported to affect between 5-10% of women of reproductive age.<sup>2, 3</sup> New Zealand studies report a similar proportion of women with PCOS although the ultrasound finding of polycystic ovaries is considerably more common, being found in 21% of randomly selected New Zealand women.<sup>4</sup> PCOS is also often undiagnosed.<sup>5</sup>

## **Cause of PCOS not fully understood**

The pathogenesis of PCOS is not fully understood.<sup>6</sup> There is some evidence of a polygenic component.<sup>7, 8</sup> Insulin resistance is an important element in the development of PCOS but there are complex interactions involving many systems (Figure 1).



**Figure 1: Pathophysiological characteristics of PCOS.** This figure illustrates the complex interactions underlying the pathophysiology of PCOS. Insulin resistance and the resulting hyperinsulinemia are responsible for the majority of the changes found in PCOS.

### Long term health risks in PCOS

It is generally accepted that women with PCOS are at increased risk of:

- Impaired glucose tolerance, metabolic syndrome, gestational diabetes and type 2 diabetes<sup>9</sup>
- Hypertension, dyslipidaemia and cardiovascular disease<sup>10</sup>
- Fertility problems
- Endometrial hyperplasia and therefore endometrial cancer<sup>11, 12</sup>

Recent studies have shown an increased risk of obstructive sleep apnoea, irrespective of BMI.<sup>12</sup> An association

between PCOS and breast and ovarian cancers has also been suggested but the evidence is conflicting.<sup>11, 13</sup>

Studies have identified that insulin resistance appears to be responsible for many of these long term health consequences.<sup>8, 14</sup> Obesity contributes to the risks, but not all women with PCOS are obese. Hyperinsulinaemia and other metabolic changes are present even in lean women with PCOS.<sup>11</sup>

There are, however, other factors often present in women with PCOS that may also contribute to these health risks. For example, unopposed oestrogens are a risk factor for endometrial hyperplasia and carcinoma. In addition, both

diabetes and obesity have been linked to an increased risk of endometrial carcinoma.

A woman with PCOS therefore may have many factors that could increase her long term health risks and it has been difficult so far to determine the exact roles of each factor.<sup>13</sup>

## Diagnosing PCOS

### Diagnostic criteria have been developed for PCOS

PCOS is a syndrome, so there is no single diagnostic test. Diagnostic criteria have been developed (Box 1) and widely adopted internationally. However, diagnosis can be difficult due to the variation in presenting symptoms and because symptoms differ with age at presentation and change over time.

### Presenting features of PCOS

Although presenting features (Box 2), age of presentation and severity of PCOS vary, a common presentation may be of a woman with a history of gradually worsening hirsutism and irregular periods, which goes back for some years. For many women however, failure to conceive may be the initial reason for presentation.

### A full history is needed

It is important when taking the history to include questions about:

- Reproductive health (menarche, past and present cycle, oligo-/amenorrhoea, menorrhagia, miscarriage, infertility)
- Presence of androgenic symptoms (acne, hirsutism, alopecia of the scalp)
- Lifestyle factors (changes in body weight, eating and exercise habits, alcohol and smoking history)
- Family history of PCOS, diabetes, obesity, hirsutism and premature male baldness.<sup>13</sup>

### Box 1: Rotterdam Consensus on Diagnostic Criteria for PCOS<sup>9</sup>

**Two out of three** of the following:

1. Oligo- or anovulation
2. Clinical and/or biochemical signs of hyperandrogenism\*
3. Polycystic ovaries\*\*

**and** exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumours, Cushing's syndrome)

\* Hirsutism, acne, male pattern baldness, elevated total or free testosterone

\*\* On ultrasound,  $\geq 12$  follicles of 2-9mm diameter and/or increased ovarian volume ( $> 10\text{mL}$ )

### Box 2: Presenting features of PCOS<sup>5, 8, 13, 14</sup>

Presenting features (% affected)

- Hyperandrogenism (hirsutism 70%, acne 30%, alopecia 10%, but not virilisation\*)
- Menstrual disturbance 60-70%
- Infertility 70%
- Obesity, particularly truncal 35-50%
- Polycystic ovaries visible on ultrasound in asymptomatic woman 22-33%
- Acanthosis nigricans 1-3% \*\*

\* Rapid development of virilisation signals a need for investigation to rule out the presence of an androgen secreting tumour.<sup>8, 15</sup>

\*\* A brown-discoloured 'velvety' texture to the skin typically in the region of the axillae and the back of the neck, often considered to be the cutaneous manifestation of insulin resistance (or hyperinsulinaemia).

**Examination includes general as well as reproductive features**

Examination of a woman with suspected PCOS should include an assessment of:

- Weight (both BMI and hip/waist ratio)
- Acne and hirsutism
- Blood pressure

Additional examination depending on the presenting features may include breast, abdominal and pelvic exam. The presence of abdominal striae could indicate weight change or Cushing’s syndrome. A bimanual examination may identify ovarian enlargement, although clinical pelvic

examination is a poor predictor of polycystic ovaries, especially if the BMI is high. The presence of features of virilisation (which may include frontal balding, deepening of the voice, broadening of the shoulders, breast atrophy, clitoromegaly and loss of vaginal rugae) may raise concerns about other serious conditions.<sup>13</sup>

**Investigation of PCOS**

A clinical or biochemical finding of increased androgen levels along with either menstrual abnormalities or polycystic ovaries on ultrasound will satisfy the current diagnostic criteria (Box 1). The initial tests recommended for diagnosis are outlined in Table 1. While not essential

**Table 1:** Recommended investigations for aiding diagnosis of PCOS

Investigation	Expected finding in PCOS	Comment
<b>Recommended investigations for diagnosis</b>		
Exclude pregnancy		Most common cause of amenorrhoea. <sup>13, 14</sup>
Pelvic ultrasound	Polycystic ovaries	Important as part of the diagnostic criteria but not a “must do” if diagnosis is made on clinical and biochemical grounds.
Free testosterone	Usually increased	More sensitive for identifying physiologically active androgens. This is calculated from total testosterone and SHBG. Very high levels of total testosterone require further investigation to rule out other causes such as late-onset congenital adrenal hyperplasia, Cushing’s syndrome, adrenal or ovarian tumour. SHBG levels are decreased in PCOS.
<b>Recommended investigations after diagnosis</b>		
Glucose		To check for glucose intolerance or diabetes. If fasting level > 5.5 mmol/L or random > 7.7 mmol/L then a glucose tolerance test is recommended.
Lipids	Usually high triglycerides, lower HDL and mildly elevated LDL. <sup>11</sup>	A fasting level may be useful in establishing cardiovascular risk.
<b>Other tests to consider</b>		
LH/FSH	LH will often be increased, FSH usually normal, giving an increased ratio	While not essential for diagnosis, some clinicians remain convinced of the value of LH testing in predicting future complications of PCOS.

**Table 2:** Tests to exclude other conditions (depending on clinical suspicion)

Test	Reason	Clinical signs
Prolactin	Very high levels may suggest a pituitary cause or medication use (especially antipsychotic medication)	Galactorrhoea Irregular or absent periods
TSH	To exclude thyroid abnormalities as a cause of menstrual irregularity <sup>14</sup>	Menstrual changes associated with other thyroid symptoms (either hypo or hyper)
Oestradiol + FSH	To help exclude premature ovarian failure (low oestradiol, very high FSH) <sup>7</sup>	Menopausal symptoms and signs in women less than 40 years
17-OH progesterone	To help exclude late-onset or non-classic congenital adrenal hyperplasia (very rare)	Difficult to distinguish clinically from PCOS. However there may be a family history of CAH, less menstrual disruption or history of early growth of pubic hair.
DHEAS	A marker for adrenal androgen production, very high levels may be associated with an adrenocortical tumour <sup>15</sup>	Rapid onset of virilising features
Androstenedione	A marker for ovarian androgen production, very high levels may be associated with an ovarian androgen secreting tumour <sup>15</sup>	Rapid onset of virilising features
24hr urine cortisol	Increased in Cushing's syndrome	Typical Cushingoid features e.g. central obesity, moon face, thinning of skin, striae, excessive sweating

for diagnosis, some clinicians still suggest testing LH/FSH. Once the diagnosis is established, fasting glucose and lipids are recommended. Other tests may be required depending on clinical suspicion, to exclude other conditions (Table 2).

## Treatment and management of PCOS

**Lifestyle modification to reduce weight is the most effective first line treatment in PCOS.**<sup>14, 16, 17</sup> Even a modest weight loss of 5% will reduce central obesity and insulin resistance and improve endocrinological abnormalities and menstrual irregularity (including increasing the rate of ovulation).<sup>17</sup> Ultimately, women who succeed in losing weight are more likely to achieve and have a healthier pregnancy and reduce their risk of gestational diabetes. Longer term benefits of weight loss result from the reduction in insulin resistance. Note that weight loss is not necessary if BMI is within normal range.

### Changes in serum endocrinology in PCOS<sup>8</sup>

There are multiple biochemical changes in women with PCOS. The key feature is the increased level of serum androgens which are responsible for most of the common presenting features:

- Increased androgens (testosterone, androstenedione and dehydro-epiandrosterone sulphate (DHEAS))
- Increased luteinising hormone (LH)
- Decreased sex hormone binding globulin (SHBG)
- Increased prolactin
- Increased oestradiol
- Increased insulin

### Do not test insulin

Fasting serum insulin is a poor measure of insulin resistance.<sup>18</sup> Although used widely in large population-based epidemiological studies, it is not recommended for use in a general practice setting. It is more useful to identify the risk factors that are associated with insulin resistance (and often therefore identify metabolic syndrome and PCOS). These risk factors include raised fasting glucose and lipid levels, high blood pressure and central obesity.

### Ethnicity and PCOS

Limited data exist on prevalence between different ethnic groups in New Zealand. A cross-sectional study of women presenting to the gynaecological clinic at National Women's Hospital who were diagnosed with PCOS showed rates for European, Māori and Pacific Island women in proportion to the general population. Although numbers were small, Indian women appeared to be over-represented and Chinese women under-represented.

What may be more important though is that Māori and Pacific Island women with PCOS were more likely to be obese and had significantly more adverse metabolic features, higher levels of androgens, triglycerides, LDL cholesterol, fasting insulin, systolic and diastolic blood pressure, and lower HDL.<sup>19</sup>

**Treatment may be required for acne and hirsutism**, which are often the major reasons for women to present. Treatment options may include anti-androgens, topical agents (particularly for acne) and local hirsutism treatments (including electrolysis and laser therapy). The combination of acne, hirsutism and obesity is likely to lower

self esteem in women with PCOS. Psychological support may be required and this may also help women achieve the recommended beneficial lifestyle changes.

**First line anti-androgenic therapy** is often in the form of a combined oral contraceptive pill containing cyproterone acetate, and/or the diuretic spironolactone (usually 100–200 mg/day), which has an anti-androgenic effect. As a second line treatment, higher dose regimens of cyproterone acetate or spironolactone may be combined with oral contraceptive pill use.

**Regulation of the menstrual cycle** may be achieved with weight loss, a combined oral contraceptive or progesterone therapy (if COC not tolerated). Most clinicians would currently recommend the use of these hormonal treatments to protect the endometrium from unopposed oestrogen stimulation in women who have chronic anovulation.<sup>11, 14</sup>

**Metformin**, which is an insulin sensitising agent, has been advocated as a treatment for PCOS. Theoretically it should decrease insulin levels and therefore reduce androgen production, and help restore the endocrinological abnormalities of PCOS. It has been suggested that it may aid weight loss, but there is currently no evidence to support this.<sup>14</sup>

There is ongoing debate regarding the appropriateness of metformin as first choice treatment in women with PCOS who are having fertility problems. It appears that in many studies metformin results in no improvement in live birth rates compared to clomiphene citrate.<sup>18, 20</sup> A multi-centre New Zealand randomised trial PCOSMIC (PCOS Metformin for Infertility with Clomiphene) will help to define the place of metformin in ovulation induction and is expected to be completed in 2008.<sup>21</sup>

**If infertility is the main presenting problem, specialist referral is recommended.** Clomiphene citrate is considered first line treatment.<sup>14, 22</sup> To avoid the risk of over-response leading to multiple pregnancy, clomiphene citrate treatment is carefully monitored through a fertility clinic (with late follicular serum oestradiol levels and ultrasound scanning

when appropriate). Weight reduction, if appropriate, remains central to the success of any treatment.

**Ongoing preventive screening of cardiovascular and endometrial disease risk factors is important** when managing women with PCOS. There are no consensus guidelines in widespread use. A sensible approach would be to check BMI and blood pressure annually, along with fasting lipids and a glucose tolerance test every three to five years in patients with low cardiovascular risk, or every one to three years where other risk factors, such as obesity, are present.

These consultations give women with PCOS the opportunity to review lifestyle factors to optimise their long term health. For women with anovulation who elect not to use endometrial protection, regular screening by transvaginal ultrasound and/or endometrial biopsy every one to two years is advisable.

#### References:

- Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. *Am J Obstet Gynecol* 1935;29:181-191
- Hart R, Hickey M, Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. *Best Pract Res Clin Obstet Gynaecol* 2004;18(5):671-683
- Azziz R, Woods KS, Rayna R et al. The Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population. *J Clin Endocrinol Metab* 2004;89(6):2745-2749
- Farquhar CM, Birdsall M, Manning P, Mitchell JM, France JT. The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women. *Aust NZ J Obstet Gynaecol* 1994;34(1):67-72
- Magnotti M, Futterweit W. Obesity and the polycystic ovary syndrome. *Med Clin North Am* 2007;91(6):1151-68
- Nestler JE. Metformin for the Treatment of the Polycystic Ovary Syndrome. *N Engl J Med* 2008;358:47-54
- Fenton A. Polycystic Ovarian Syndrome. *NZFP* 2005;32(2):103-105
- Balen A. The current understanding of polycystic ovary syndrome. *Obstetrician and Gynaecologist* 2004;6:66-74
- The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertil Steril* 2004;81(1):19-25
- Rizzo M, Bernesis K, Carmina E, Rina GB. How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome? *Am J Obstet Gynecol* 2008;198(1):28e1-5
- Catrrall FR & Healy DL. Long-term metabolic, cardiovascular and neoplastic risks with polycystic ovary syndrome. *Best Pract Res Clin Obstet Gynaecol* 2004;18(5):803-812
- Ehrmann DA. Polycystic ovary syndrome. *N Engl J Med* 2005;352:1223-1236
- Fraser IS. Current recommendations for the diagnostic evaluation and follow-up of patients presenting with symptomatic polycystic ovary syndrome. *Best Pract Res Clin Obstet Gynaecol* 2004;18(5):813-823
- National Health Service. Clinical Knowledge Summaries. Polycystic ovary syndrome. Available from <http://cks.library.nhs.uk/> Accessed February 2008
- Smith G. Investigation and Diagnosis of Polycystic Ovary Syndrome. *Path Review* 2007. Medlab, Hamilton
- Meyer C, McGrath P, Teede HJ. Effects of Medical Therapy on Insulin Resistance and the Cardiovascular System in Polycystic Ovary Syndrome. *Diabetes Care* 2007;30:471-478
- Balen A. Should obese women with polycystic ovary syndrome receive treatment for infertility? *BMJ* 2006;332:434-435
- Samaras K, McElduff A, Twigg et al. Insulin levels in insulin resistance: phantom of the metabolic opera? *Med J Aust* 2006;185(3):159-161
- Williamson K, Gunn AJ, Johnson N, Milsom SR. The impact of ethnicity on the presentation of polycystic ovarian syndrome. *Aust NZ J Obstet Gynaecol* 2001;41(2):202-206
- Lord J, Flight IHK, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. *BMJ* 2003;327:951-954
- Johnson NP. No more surrogate end-points in randomised trials - the PCOSMIC trial protocol for women with polycystic ovary syndrome using metformin for infertility with clomiphene. *Aust N Z J Obstet Gynaecol* 2006;46:141-5
- Legro RS, Barnhart HX, Schreff WD et al. Clomiphene, Metformin, or Both for Infertility in the Polycystic Ovary Syndrome. *New Engl J Med* 2007;356:551-556